Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

APP Generic Cisplatin To Launch At 12.5% Discount To Bristol's Platinol AQ

Executive Summary

American Pharmaceutical Partners' generic version of Bristol-Myers Squibb's Platinol AQ (cisplatin) will be launched at a 12.5% discount to the branded product, following a court decision declaring Bristol's patent invalid.

You may also be interested in...



Generic Exclusivity Does Not Apply After Challenged Patent Expires - FDA

The 180-day exclusivity for first generics cannot extend beyond the expiration of the patent challenged in the ANDA's paragraph IV certification, FDA said in granting exclusivity to American Pharmaceutical Partners for generic cisplatin even though it was not the first company to submit an ANDA for the drug.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
UsernamePublicRestriction

Register

PS035152

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel